{
    "clinical_study": {
        "@rank": "143058", 
        "brief_summary": {
            "textblock": "This is an expanded access program (EAP) for participants who have progressed after prior\n      systemic therapy including ipilimumab, and V-raf murine sarcoma viral oncogene homolog B1\n      (BRAF) inhibitor or mitogen-activated protein kinase (MEK) enzyme inhibitor when indicated.\n      Participants cannot be eligible for or have participated in any pembrolizumab (MK-3475)\n      clinical trial."
        }, 
        "brief_title": "Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)", 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Unresectable (Stage III) or metastatic melanoma\n\n          -  Failed or progressed on standard of care systemic therapy including ipilimumab\n\n          -  Willing to sign Informed Consent\n\n          -  Eastern Cooperative Oncology Group Performance status of 0 or 1\n\n          -  Female participants of childbearing potential must be willing to use adequate\n             contraception or be surgically sterile, or abstain from heterosexual activity\n             starting with the first dose of treatment through at least 120 days after the last\n             dose of pembrolizumab\n\n          -  Male participants must agree to use an adequate method of contraception starting with\n             the first dose of treatment through 120 days after the last dose of pembrolizumab\n\n          -  Adequate organ function\n\n        Exclusion criteria:\n\n          -  Eligible for an accessible pembrolizumab clinical study or previously participated in\n             a pembrolizumab clinical study\n\n          -  Eligible for treatment with a marketed BRAF inhibitor or MEK inhibitor\n\n          -  Not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or\n             better due to prior chemotherapy, radioactive, or biological cancer therapy\n             (including monoclonal antibodies)\n\n          -  Not recovered from minor or major surgery and less than 4 weeks from major surgery\n\n          -  History of life-threatening or severe immune-related adverse events on treatment with\n             another immunotherapy\n\n          -  Expected to require any other form of systemic antineoplastic therapy while receiving\n             pembrolizumab\n\n          -  History of clinically severe autoimmune disease (e.g., requires chronic\n             immunosuppressive therapy)\n\n          -  History of pneumonitis, organ transplant, human immunodeficiency virus (HIV), active\n             hepatitis B or hepatitis C\n\n          -  Active central nervous system metastases, carcinomatous meningitis, untreated brain\n             metastases\n\n          -  Pregnant or breastfeeding, or expecting to conceive or father children within the\n             projected duration of treatment with pembrolizumab\n\n          -  Active infection requiring systemic therapy"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "id_info": {
            "nct_id": "NCT02083484", 
            "org_study_id": "3475-030"
        }, 
        "intervention": {
            "description": "Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.", 
            "intervention_name": "Pembrolizumab", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "official_title": "Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options", 
        "overall_contact": {
            "email": "mk3475us@idispharma.com", 
            "last_name": "Idis", 
            "phone": "1-855-478-4347"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Available", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083484"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "June 2014"
    }
}